Thomas A Abrams

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer
    Thomas A Abrams
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 29:3255-62. 2011
  2. ncbi request reprint Chemotherapy Usage Patterns in a US-Wide Cohort of Patients With Metastatic Colorectal Cancer
    Thomas A Abrams
    Affiliations of authors Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA TAA, DS, JAM, CSF IntrinsiQ, LLC, an AmerisourceBergen Specialty Group Company, Burlington, MA GM, JM
    J Natl Cancer Inst 106:djt371. 2014
  3. ncbi request reprint Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Endocr Relat Cancer 19:615-23. 2012
  4. pmc A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
    Jason E Faris
    Department of Medical Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USA
    Invest New Drugs 30:1614-20. 2012
  5. pmc Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 19:1557-66. 2013
  6. pmc A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 68:293-300. 2011
  7. pmc Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 7:e38231. 2012
  8. pmc Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 117:5094-102. 2011
  9. pmc Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab
    Raymond C Wadlow
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 17:14. 2012
  10. pmc Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients
    Douglas A Rubinson
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Invest New Drugs 32:113-22. 2014

Detail Information

Publications12

  1. doi request reprint Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer
    Thomas A Abrams
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 29:3255-62. 2011
    ..Previous studies have examined predictors for initiation of adjuvant chemotherapy in stages II and III colon cancer. However, little is known regarding the use of specific chemotherapy regimens or treatment duration...
  2. ncbi request reprint Chemotherapy Usage Patterns in a US-Wide Cohort of Patients With Metastatic Colorectal Cancer
    Thomas A Abrams
    Affiliations of authors Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA TAA, DS, JAM, CSF IntrinsiQ, LLC, an AmerisourceBergen Specialty Group Company, Burlington, MA GM, JM
    J Natl Cancer Inst 106:djt371. 2014
    ..Since the introduction of biologic therapies for the treatment of metastatic colorectal cancer (mCRC), few studies have examined patterns of care or predictors of specific treatment approaches...
  3. ncbi request reprint Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Endocr Relat Cancer 19:615-23. 2012
    ..monthly in combination with everolimus 10  mg daily is feasible and associated with preliminary evidence of antitumor activity in patients with advanced neuroendocrine tumors. Further studies evaluating this combination are warranted...
  4. pmc A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
    Jason E Faris
    Department of Medical Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USA
    Invest New Drugs 30:1614-20. 2012
    ..MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin-β family. We conducted an open-label Phase II study with MKC-1 in patients with advanced pancreatic cancer...
  5. pmc Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 19:1557-66. 2013
    ..We conducted a single-arm phase II study of cediranib, a pan-VEGFR tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC)...
  6. pmc A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 68:293-300. 2011
    ..We performed a prospective, phase II study of 2ME2, administered in combination with bevacizumab, in patients with advanced carcinoid tumors...
  7. pmc Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 7:e38231. 2012
    ..To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer...
  8. pmc Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 117:5094-102. 2011
    ..The phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway plays a critical role in the pathogenesis of hepatocellular carcinoma (HCC). We performed a single-arm, phase 1/2 study of everolimus in patients with advanced HCC...
  9. pmc Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab
    Raymond C Wadlow
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 17:14. 2012
    ..We performed a single-arm phase II trial of panitumumab in patients with KRAS wild-type metastatic colorectal cancer that had progressed on prior cetuximab...
  10. pmc Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients
    Douglas A Rubinson
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Invest New Drugs 32:113-22. 2014
    ..Pertuzumab is a monoclonal antibody that blocks HER2 hetero-dimerization; thus the combination of pertuzumab and cetuximab could possibly overcome cetuximab resistance...
  11. ncbi request reprint First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 19:920-8. 2013
    ..This first-in-man clinical trial was conducted to evaluate the safety, pharmacokinetic characteristics, and preliminary efficacy of GC33 in patients with advanced HCC...
  12. doi request reprint Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Lancet Oncol 11:48-54. 2010
    ....